摘要
目的探索研究前列舒通联合左氧氟沙星治疗慢性细菌性前列腺炎的临床效果。方法选取我院门诊收治的慢性细菌性前列腺炎患者总共132例,随机平均分成观察组和对照组。对照组患者给予左氧氟沙星胶囊治疗,4周为1个疗程。观察组患者在左氧氟沙星胶囊治疗的基础上给予前列舒通胶囊联合治疗,4周为1个疗程。经过一个疗程的治疗,观察两组患者的治疗效果。结果观察组患者总有效率为98.48%,明显高于对照组的81.81%,差异显著(P<0.05),具有统计学意义。观察组患者治疗后的疾病复发率为3.03%,明显低于对照组患者的19.70%,差异显著(P<0.05),具有统计学意义。观察组患者治疗后药物不良反应发生率为7.58%,对照组患者治疗后药物不良反应发生率为9.09%,观察组患者的药物不良反应发生率与对照组相比没有显著差异(P>0.05),不具有统计学意义。结论前列舒通联合左氧氟沙星治疗慢性细菌性前列腺炎具有很好的临床疗效,复发率低,药物安全有效,值得临床推广使用。
Objective To explore the clinical effect of prostaconk combined with levofloxacin in the treatment of chronic bacterial prostatitis. Methods A total of 132 patients with chronic bacterial prostatitis treated in our hospital were randomly divided into the observation group and the control group. The patients in the control group were treated with left Ofloxacin Capsules for 1 periods of 4 weeks. On the basis of left Ofloxacin Capsules treatment, the patients in the observation group were treated with the combination of the proactive sholong capsule and the 1 course of 4 weeks. After a course of treatment, the therapeutic effect of two groups of patients was observed. Results The total effective rate of the patients in the observation group was 98.48%, which was significantly higher than that of the control group（81.81%）. The difference was significant（P〈0.05）, with statistical significance. The recurrence rate of the patients in the observation group was 3.03% after treatment, which was significantly lower than that of the control group（19.70%）. The difference was significant（P〈0.05）, with statistical significance. The incidence of adverse drug reactions in the observation group was 7.58% after treatment. The incidence of adverse drug reactions in the control group was 9.09% after treatment. The incidence of adverse drug reactions in the observation group was not significantly different from that in the control group（P〉0.05）. Conclusion Prostaconk combined with levofloxacin has a good clinical effect in the treatment of chronic bacterial prostatitis, with low relapse rate and safe and effective drug. It is worthy of clinical promotion.
作者
刘强
陈国伟
侯刚剑
LIU Qiang;CHEN Guowei;HOU Gangjian(Xinjiang Production and Construction Corps Second Division Korla Hospital, Korla, Xinjiang 841000, China)
出处
《新疆医学》
2018年第4期433-435,共3页
Xinjiang Medical Journal
